drugset / Trial / NCT01736423

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

NCT01736423

Phase 3 Completed 151 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of YM060 once daily for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) for a long-term period (up to 52 weeks).

Timeline

Start
2012-09
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramosetron Small molecule 2.5 ug Oral
Subject Ramosetron Small molecule 5 ug Oral